Robert C. Goeltz II, Chief Financial Officer at Arcus Biosciences, Inc. (RCUS), bought 5,000 shares at $21.57 ($108K) on 2020-09-09, disclosed to the SEC on 2020-09-09.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| RCUS | SELL | 2025-12-18 | $557K | — | Filing → |
| RCUS | SELL | 2025-11-26 | $125K | — | Filing → |
| RCUS | SELL | 2025-10-29 | $100K | — | Filing → |